Menu
Recent Post
Related Posts
Raising the Voice: A Comment on Race and Ethnic Disparities in Alzheimer’s Disease Clinical Research
Alzheimer’s Disease clinical research has faced a significant challenge for a long time in achieving diverse racial or ethnic representation in clinical trials. Many of these issues are rooted in
Hypertension as a Risk Factor for Cognitive Decline
Hypertension, or high blood pressure, significantly impacts public health worldwide. Hypertension is well recognized for its role in cardiovascular disease, revealing implications for cognitive decline and dementia. Increasing clinical evidence
IGC PHARMA Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.
Parkinson’s awareness month
____________________________
Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer’s Research
By: Faith Ashmore Benzinga Staff Writer As of 2023,, the estimated number of Americans living with Alzheimer’s disease was 6.7 million. However, a lesser-known subsection of Alzheimer’s is Agitation in dementia
